An outside panel of experts to the FDA is scheduled to discuss the confirmatory study of Amgen's (AMGN) non-small cell lung cancer drug Lumakras on October 5, 2023.Lumakras was granted accelerated approval by the FDA in May 2021, for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer.The confirmatory study is intended to support the conversion of the accelerated approval to a traditional approval.The drug generated global sales of $77 million in the second quarter of 2023, same as that in the comparable year-ago quarter.AMGN closed Wednesday’s trading at $265.44.